Skip to content Skip to footer
Subscribe Now
VIEWPOINTS

Unlocking Approval: Sofie Berg from AbbVie in a Riveting Conversation with PharmaShots 

Shots:  AbbVie adds an eighth indication to Rinvoq’s label with the European Commission’s approval for treating adult patients with giant cell arteritis (GCA)  Sofie Berg, Therapeutic Area Head of International Immunology at AbbVie, in a conversation with PharmaShots, shares insights from the SELECT-GCA trial evaluating Rinvoq in GCA, highlighting both primary and secondary endpoints  Rinvoq…
July 9, 2025

Read more

INSIGHTS+

Key Biosimilars Events of June 2025  

Shots:        Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency         Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients         Alvotech & Advanz Pharma Secure the CHMP’s Positive Opinion for AVT06. Our…
July 8, 2025

Read more

VIEWPOINTS

Patient Insights: Jerry Kelleher in an Illuminating Conversation with PharmaShots 

Shots:  Abbott’s AVEIR DR is the first in the world dual-chamber leadless pacemaker  Jerry Kelleher, a clinical trial participant in the AVEIR DR study, shares his transformative journey with PharmaShots  Explore Jerry’s miraculous recovery with AVEIR DR, which helped enhance his quality of life   Saurabh: Jerry, can you take us back to life and describe…
July 7, 2025

Read more

THOUGHTSPOT

Choose the Right Microplate Reader: Strategic Guide for Advanced Biologics Development

In the competitive and ever-evolving world of biologics and protein therapy, each decision can significantly influence the trajectory of your research outcomes. Among these critical choices, selecting the optimal microplate reader stands out. Far from being just another lab instrument, your choice here can dramatically shape the accuracy, efficiency, and scalability of your scientific discoveries.…
July 7, 2025

Read more

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (Jun 30, 2025 – Jul 04, 2025)    

This week, PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, and Biosimilar. Check out our full report below:  Neurocrine Reports Data From KINECT-HD Study Evaluating INGREZZA in Huntington’s Disease (HD)  Read More: Neurocrine  UCB Reports the P-III Data of Fenfluramine in CDKL5 Deficiency Disorder (CDD) Patients  Read More: UCB  …
July 4, 2025

Read more

THOUGHTSPOT

Is Addiction Hereditary?

When you think about addiction, you likely wonder if your family history puts you at risk. The answer isn't straightforward, genetics account for 40-60% of addiction vulnerability, while your environment shapes the rest. Your DNA influences how your brain responds to substances, but it doesn't seal your fate. Understanding this genetic component reveals why addiction…
July 4, 2025

Read more

20 Innovative Digital Therapeutics Companies of 2025
TOP 20

20 Innovative Digital Therapeutics Companies of 2025 

Shots:   The integration of innovative technologies in healthcare, such as digital health platforms and AI-enabled applications, is transforming the way diseases are detected, diagnosed, treated, and prevented  The global Digital Health market is expected to reach $197.88B in 2025 and grow at a CAGR of 6.88%, reaching $258.25B by 2029  PharmaShots presents a concise report…
July 3, 2025

Read more

VIEWPOINTS

Regeneron at ASH’24: Aafia Chaudhry in a Stimulating Dialogue Exchange with PharmaShots 

Shots:   Recently, Regeneron presented Odronextamab’s data in treating patients with different B-NHL subtypes (OLYMPIA studies) and marginal zone lymphoma (ELM-2 study)  Aafia Chaudhry, Vice President, Global Program Head for Hematology-Oncology at Regeneron, discusses Odronextamab’s ongoing studies as monotherapy and in combination to treat various malignancies  Aafia shares the upcoming PDUFA date on July 30th for…
July 2, 2025

Read more

Q1 2025
INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2025 

Shots:    Q2’2025 highlights major acquisitions in the pharma and biotech industry along with collaboartion. The talk of the town remained Blueprint Medicines’ acquisition by Sanofi for ~$9.5B    The quarter highlighted Collaboartion, including Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid    PharmaShots brings the Quarterly digest compiling insights from…
July 1, 2025

Read more

Load more